Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
科研成果: 期刊稿件 › 文章 › 同行评审
42
引用
（Scopus）